In certain instances, we may earn revenue when a reader makes a purchase or completes a form through our pages or on a partner’s website. We adhere to a strict 
Elon Musk’s Neuralink has set its sights on an ambitious goal: restoring vision to the blind through a brain chip called Blindsight. The experimental device recently received FDA breakthrough designation, accelerating its path toward Neuralink human trials planned for late 2025.
But while Musk promises eventual “superhuman vision,” neuroscientists warn that the reality will be far more limited than the hype suggests.
The announcement has sparked intense debate in the scientific community about what’s truly possible with current brain-computer interface (BCI) technology.
As Neuralink, the company behind the famous brain computer interface, races to begin human trials of its blindsight device, experts are working to separate realistic expectations from science fiction dreams, while acknowledging that even limited artificial vision could transform lives for those who have lost their sight.
Key Takeaways
- Neuralink’s Blindsight device received FDA breakthrough designation in September 2024
- The brain chip works by implanting a microelectrode array directly into the visual cortex, bypassing damaged eyes and optic nerves.
- Initial vision quality will be extremely low-resolution, comparable to 1970s Atari graphics.
- Leading neuroscientists express skepticism about claims of eventual “superhuman vision.”
- No pricing information is available yet, and the technology remains years away from commercial availability.
- Show Full Guide
How Neuralink Blindsight Works
The Neuralink Blindsight device represents a fundamentally different approach to vision restoration than previous attempts.
Rather than trying to repair or replace damaged eyes or optic nerves, Elon Musk’s Neuralink brain chip bypasses these components entirely by directly stimulating the visual cortex, the part of the brain that processes visual information.
The device works via a microelectrode array implant in the visual cortex area of the brain that then activates neurons, which, in turn, form an image in the brain.
This array likely contains over 1,000 electrodes, each capable of stimulating individual neurons to create points of light called phosphenes. When multiple phosphenes are activated in patterns, they can theoretically form simple images.
Visual prostheses work by capturing visual information with a video camera, typically attached to glasses or a headset. Then, a processor converts the data to an electrical signal that can be relayed to the nervous system.
Source: Neuralink
The Surgical Process
Implementing the Neuralink Blindsight system would require complex neurosurgery to implant the electrode array directly onto the surface of the brain’s visual cortex.
Neuralink has developed what it calls a “sewing machine-like” robot capable of precisely inserting ultra-thin electrode threads, each just 4 to 6 micrometers wide, into brain tissue while avoiding blood vessels.
The company has been testing these implants in monkeys, with Musk claiming in March 2024 that the devices were working in trials and that “no monkey had died or been seriously injured due to a Neuralink device, contradicting earlier reports.”
However, veterinary records have previously shown complications with surgically implanted electrodes in test animals.
What Blindsight Promises vs. Reality
In his characteristic style, Elon Musk has made sweeping promises about what the Blindsight neuralink implant will eventually achieve.
Musk has said that the device will allow those who have lost sight in both eyes and their optic nerve to see. The requirement is that their visual cortex is functioning and intact. He also said it will even allow those born blind to see for the first time.
Most controversially, Musk has claimed that while initial vision will be low-resolution, “eventually it has the potential to be better than natural vision and enable you to see in infrared, ultraviolet or even radar wavelengths, like Geordi La Forge.”
This reference to the Star Trek character with enhanced vision captures Musk’s ultimate ambition for the technology.
The Blindsight device from Neuralink will enable even those who have lost both eyes and their optic nerve to see.
Provided the visual cortex is intact, it will even enable those who have been blind from birth to see for the first time.
To set expectations correctly, the vision… https://t.co/MYLHNcPrw6 pic.twitter.com/RAenDpd3fx
— Elon Musk (@elonmusk) September 17, 2024
The Scientific Reality Check
Leading neuroscientists have pushed back strongly against these claims.
Ione Fine, a computational neuroscientist at the University of Washington who previously worked for vision prosthetics company Second Sight, explained:
“[Musk] will build the best cortical implant we can build with current technology. It will not produce anything like normal vision. [Yet] it might produce vision that can transform the lives of blind people.”
The fundamental challenge lies in how the brain processes visual information.
Unlike a computer screen, where more pixels simply mean better resolution, the visual cortex operates through complex networks of neurons with overlapping receptive fields. Simply adding more electrodes doesn’t translate to clearer vision.
Curing blindness, and applying it on a large scale, is a medical breakthrough that is possible, and potentially likely, in our lifetime. Truly extraordinary.
The @neuralink BlindSight project will have its first human implant in 2025, installing a device that aims to restore… pic.twitter.com/z30Y13mbZC
— Ian Rowe (@IanVRowe) June 20, 2025
Expert Reactions: Excitement Meets Skepticism
Despite the skepticism about Musk’s grander claims, some researchers see serious potential in Neuralink’s approach. The company’s resources and engineering capabilities could advance the field a lot.
The breakthrough device designation from the FDA represents meaningful progress, signaling that regulators see potential in the technology to address an unmet medical need.
With Neuralink’s substantial funding – $650 million raised in the latest funding round – the company has resources that academic researchers can only dream of.
However, some neuroscientists express deep concerns about both the technology and how it’s being marketed.
Gislin Dagnelie, a vision scientist at Johns Hopkins University, has worked on multiple vision prosthetic trials, said:
“I’m leery about the fact that they are very superficial in their description of the devices. There’s no clear evaluation or pre-clinical work that has been published. It’s all based on: ‘Trust us, we’re Neuralink.'”
The lack of peer-reviewed publications or detailed technical specifications has frustrated researchers in the field.
The announcement has generated mixed reactions on social media platforms. Some users on X have pointed out that other institutions have been working on similar technology for years without the fanfare.
Several companies developing artificial vision prosthetics have reached clinical trials only to struggle financially. Some have even left patients without support. The fate of Second Sight, which left patients with obsolete retinal implants after bankruptcy, serves as a cautionary tale.
Potential Use Cases & Limitations
Who Could Benefit
With the Blindsight device, Neuralink could potentially help several groups of visually impaired individuals:
- Those who lost vision due to eye trauma or disease but retain an intact visual cortex
- People born blind whose visual cortex developed normally despite a lack of visual input
- Individuals with damaged optic nerves from conditions like glaucoma
- Patients whose retinal implants have failed or become obsolete
Current Limitations
However, the technology faces significant limitations that Musk’s announcements often gloss over.
The initial resolution will be extremely low – Musk himself admits it will be “like Atari graphics,” referring to the blocky visuals of 1970s video games.
The device also requires an intact and functioning visual cortex, meaning it won’t help individuals whose blindness stems from cortical damage due to stroke, injury, or certain genetic conditions.
Additionally, the brain’s ability to adapt to artificial visual input remains poorly understood, especially for those blind from birth who have never developed normal visual processing pathways.
The Road to Neuralink Human Trials
Musk announced at a company event that Neuralink plans to conduct its first human implant of the Blindsight Neuralink chip by late 2025. He said:
“We’re hoping later this year to do our first device implant for a human, enabling someone who is completely blind to see. It will be low-res at first, so I want to set expectations accordingly.”
The company is already recruiting participants with vision loss for studies in the United States, Canada, and the United Kingdom.
However, even with FDA breakthrough designation, the path to approval requires extensive safety and efficacy testing that typically takes years.
Brain surgery carries inherent risks, including infection, bleeding, and scarring. Long-term effects of having electrodes in the brain remain unknown, and the challenge of maintaining sterile, functional implants over decades poses significant engineering hurdles.
Comparing Blindsight to Existing Technologies
Several other approaches to vision restoration are in development or limited use:
The Intracortical Visual Prosthesis Project, led by Philip Troyk, has already implanted a 400-electrode device in human patients, demonstrating proof of concept for cortical stimulation.
After two years of testing, the ICVP has shown that participants gained “an improved ability to navigate and perform basic, visually guided tasks.”
Retinal implants like the now-defunct Argus II from Second Sight took a different approach by stimulating remaining retinal cells. While these showed promise, they were limited to patients with some intact retinal function and ultimately failed commercially.
The Gennaris Bionic Eye from Monash University in Australia uses multiple small implants on the brain’s surface rather than a single large array, potentially offering greater flexibility in electrode placement.
Source: Monash University
Neuralink’s advantages primarily lie in its resources and engineering capabilities, rather than in fundamental breakthroughs.
The company’s high electrode count, advanced surgical robot, and wireless data transmission represent incremental improvements over existing technologies.
However, whether these engineering advances can overcome the fundamental neuroscience challenges remains to be seen.
The Future of Vision Restoration
Near-Term Realistic Outcomes
In the next five years, successful Blindsight trials might produce:
- Basic light perception and motion detection
- Ability to locate bright objects against dark backgrounds
- Enhanced navigation in familiar environments
- Simple shape recognition for large objects
These modest improvements could still significantly enhance the quality of life for blind individuals when combined with existing tools like canes and guide dogs.
Long-Term Possibilities
Looking decades ahead, advances in neuroscience understanding could potentially enable:
- Higher resolution vision through better electrode designs
- Improved brain-computer interfaces that adapt to individual neural patterns
- Integration with artificial intelligence for enhanced image processing
- Combination with other sensory augmentation technologies
However, Musk’s vision of superhuman sight detecting non-visible wavelengths remains highly speculative and unsupported by current neuroscience.
The Bottom Line
While Neuralink’s Blindsight is a serious engineering achievement that could provide limited artificial vision to some blind individuals, the gap between Musk’s promises and scientific reality remains vast.
The technology may eventually offer meaningful quality-of-life improvements as an assistive tool, but expectations of restored natural vision – let alone superhuman capabilities – are premature at best and misleading at worst.
As human trials approach, maintaining realistic expectations while pursuing genuine innovation will be crucial for both patient welfare and the field’s credibility.
FAQs
Is Neuralink going to restore eyesight?
Is Blindsight FDA-approved?
How much does the Neuralink for blindness cost?
What do neuroscientists think of Neuralink?
References
- Elon Musk on X (X)
- Neuralink’s Blindsight Implant Won’t Deliver Natural Sight (IEEE Spectrum)
- Neuralink raises $650 million Series E | Updates (Neuralink)
- News & Updates – Page 49 – Pattern of USA Inc. (Pattern of USA)
- Their Bionic Eyes Are Now Obsolete and Unsupported (IEEE Spectrum)
- Neuralink Update, Summer 2025 (YouTube)
- The Intracortical Visual Prosthesis Project (ResearchGate)
- Gennaris Bionic Eye – Art, Design and Architecture (Monash)
